Federated Hermes, Inc. Spero Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.42 - $1.95 $3,132 - $4,301	-2,206 Reduced 45.46%	2,647 $3,000
Q1 2023 May 08, 2023	BUY	$1.35 - $2.0 $6,404 - $9,488	4,744 Added 4352.29%	4,853 $7,000
Q4 2022 Feb 13, 2023	SELL	$1.55 - $2.12 $2,856 - $3,907	-1,843 Reduced 94.42%	109 $0
Q3 2022 Nov 14, 2022	SELL	$0.68 - $2.2 $426 - $1,379	-627 Reduced 24.31%	1,952 $4,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $7.44 $1,908 - $19,187	2,579 New	2,579 $2,000
Q2 2021 Aug 16, 2021	SELL	$12.22 - $15.79 $115,760 - $149,578	-9,473 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$13.23 - $21.48 $125,327 - $203,480	9,473 New	9,473 $139,000

14.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $29.1M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.